Chembio Diagnostics Reports Fourth Quarter and Full Year 2017 Financial Results

- March 9th, 2018

Chembio Diagnostics (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: Achieved total revenue of $24.0 million of which net product sales were $19.3 million for the full year 2017, increases of 34% … Continued

Chembio Diagnostics (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

  • Achieved total revenue of $24.0 million of which net product sales were $19.3 million for the full year 2017, increases of 34% and 41% respectively, over prior year
  • Received $8.5 million 2018 purchase commitment from Bio-Manguinhos in Brazil for DPP® HIV Assays and DPP® Leishmania Assays
  • Won three-year, $15.8 million total contract value tender from the Ethiopian Pharmaceuticals Fund and Supply Agency to deliver HIV STAT-PAK® Assays between 2018-2020
  • Received conditional award of $1.5 million to $4.9 million in 2018-2019 from UNICEF for DPP® Zika Systems

Click here to read the full press release.

Read our FREE medical device report today

 

 

Get My Free Report  

Leave a Reply